SMAD3 and pulmonary fibrosis: The data from the bleomycin-induced pulmonary fibrosis animal model also supported the in vitro results, demonstrating that E966-0530-45418 administration significantly decreased the phosphorylation of Smad3 at T179, further reducing fibrosis-associated protein expression (Figure 8).